Market Estimates
Valuation Metrics
Financials
Trading Trends
MLYS News & Events
Events Timeline

No data
News
People Also Watch
Frequently Asked Questions
What is Mineralys Therapeutics Inc (MLYS) stock price today?
The current price of MLYS is 33.37 USD — it has increased 0.72 % in the last trading day.
What is Mineralys Therapeutics Inc (MLYS)'s business?
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and in subjects with hypertension and OSA.
What is the price predicton of MLYS Stock?
Wall Street analysts forecast MLYS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLYS is 47.29 USD with a low forecast of 26.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
What is Mineralys Therapeutics Inc (MLYS)'s revenue for the last quarter?
Mineralys Therapeutics Inc revenue for the last quarter amounts to -41.13M USD, decreased -31.57 % YoY.
What is Mineralys Therapeutics Inc (MLYS)'s earnings per share (EPS) for the last quarter?
Mineralys Therapeutics Inc. EPS for the last quarter amounts to -28872000.00 USD, decreased -42.51 % YoY.
What changes have occurred in the market's expectations for Mineralys Therapeutics Inc (MLYS)'s fundamentals?
How many employees does Mineralys Therapeutics Inc (MLYS). have?
Mineralys Therapeutics Inc (MLYS) has 51 emplpoyees as of January 10 2026.
What is Mineralys Therapeutics Inc (MLYS) market cap?
Today MLYS has the market capitalization of 2.64B USD.


![an image of [object Object]](/_next/image?url=https%3A%2F%2Fd5bp8bijhhba2.cloudfront.net%2Fimage%2Fcover_image%2F20260108050406_fd631ca9cc459953cfe9cd75ca0ad768.jpg&w=384&q=75)
![an image of [object Object]](/_next/image?url=https%3A%2F%2Fd5bp8bijhhba2.cloudfront.net%2Fimage%2Fcover_image%2F20260106213046_64b4edc24b52a5a2768bebfe7db0d452.jpeg&w=384&q=75)
![an image of [object Object]](/_next/image?url=https%3A%2F%2Fd5bp8bijhhba2.cloudfront.net%2Fimage%2Fcover_image%2F20251231020421_fd631ca9cc459953cfe9cd75ca0ad768.jpg&w=384&q=75)